No Data
No Data
Enlivex Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | Enlivex Therapeutics Ltd : H.c. Wainwright Raises Target Price to $7 From $6
Enlivex Therapeutics Announces Investor Webinar To Discuss Interim Data From Phase I/II Allocetra Trial In Knee Osteoarthritis On March 5, 2025, At 11:00 A.m. ET
Enlivex Announces Interim Six-month Efficacy Data From Phase I Stage Of Its Randomized, Multi-Country Phase I/II Allocetra Trial In Patients With Moderate To Severe Knee Osteoarthritis.
Enlivex Therapeutics Completes Initial Dosing in Phase I Psoriatic Arthritis Trial
Israel's Health Ministry Backs Enlivex Therapeutics (NASDAQ:ENLV) for Sheba Medical Center Trials